AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Actuate Therapeutics, Inc. Common stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00NK7LK12
0.48▼ 0.04 (-7.94%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.52
Day's Range
0.45 – 0.56
52-Week Range
0.41 – 7.90
Volume
253.5K
Avg Volume
330.6K
Share Statistics
Shares Outstanding
Employees
12
Exchange
XNAS
Listed
2024-08-13
Share count as of August 13, 2026

Actuate Therapeutics, Inc. Common stock (ACTU) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Actuate Therapeutics, Inc. Common stock (ACTU)
What is Actuate Therapeutics, Inc. Common stock's Market Cap?
Actuate Therapeutics, Inc. Common stock's Market Cap is $11.4M, based on as-reported figures from SEC (XBRL) filings.
What is Actuate Therapeutics, Inc. Common stock's Enterprise Value?
Actuate Therapeutics, Inc. Common stock's Enterprise Value is $7.0M, based on as-reported figures from SEC (XBRL) filings.
What is Actuate Therapeutics, Inc. Common stock's Net Income (TTM)?
Actuate Therapeutics, Inc. Common stock's Net Income (TTM) is -$20.5M, based on as-reported figures from SEC (XBRL) filings.
What is Actuate Therapeutics, Inc. Common stock's Diluted EPS (TTM)?
Actuate Therapeutics, Inc. Common stock's Diluted EPS (TTM) is -0.85, based on as-reported figures from SEC (XBRL) filings.
What is Actuate Therapeutics, Inc. Common stock's Net Debt?
Actuate Therapeutics, Inc. Common stock's Net Debt is -$4.4M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ACTUAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Loss from operations
Other income (expense):
Interest expense
Interest and Dividend Income (Non-Bank)
Total other income, net
Net loss
Earnings Per Share (Basic)
Earnings Per Share (Diluted)